APVO News and Press, Aptevo Therapeutics Inc. From 06/09/22

Aptevo Therapeutics (NASDAQ:APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase 1b expansion trial for lead candidate APVO436 in acute myeloid leukemia (AML). According to early data ...

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date Cohort 3 Monotherapy Patient Achieved Bone Marrow Complete Remission Company Also Reports Myelodysplastic Syndrome Patient Enrolled in Dose Escalation Trial Remains Stable an...

Aptevo Therapeutics press release (NASDAQ:APVO): Q1 GAAP EPS of -$1.59 misses by $0.66. Revenue of $3.11M (+28.5% Y/Y) misses by $0.64M. For further details see: Aptevo Therapeutics GAAP EPS of -$1.59 misses by $0.66, revenue of $3.11M misses by $0.64M

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologie...

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing...

Guardforce AI (GFAI) +46% is expanding it footprint by establishing subsidiaries in Dubai and Australia. IGM Biosciences (IGMS) +32% on proposed stock offering. Hycroft Mining Holding (HYMC) +23% GameStop, AMC and Bed Bath pull off a meme stock comeback. Nielsen Holdi...

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therape...

Gainers: JX Luxventure Limited (LLL) +43%. Alpha Tau Medical (DRTS) +37%. Takung Art (TKAT) +31%. Emclaire Financial (EMCF) +32%. BiondVax (BVXV) +30%. Mercurity Fintech Holding (MFH) +26%. INmune Bio (INMB) +19%. Gracell (GRCL) +21%. Aptevo (APVO) +21%. Lilium (LILM) +20%. LiqTech Internatio...

The shares of clinical-stage biotech, Aptevo Therapeutics (NASDAQ:APVO +24.2%) have reached over a two-after recording the biggest intraday gain since November as the investors react to the company’s better-than-expected financials for 2021. Revenue for the period rose ~185% YoY to $12...

Gainers: BiondVax Pharmaceuticals (BVXV) +39%. Alpha Tau Medical (DRTS) +38%. CollPlant Biotechnologies (CLGN) +10%. Aptevo Therapeutics (APVO) +8%. HOOKIPA Pharma (HOOK) +8%. Losers: Sonendo (SONX) -11%. Creative Medical Technology (CELZ) -9%. Lan...